Carcinogenesis, Vol. 21, No. 8, 1527-1530,
August 2000
© 2000 Oxford University Press
Molecular Epidemiology and Cancer Prevention |
Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis
1 Department of Epidemiology and
2 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Epidemiological studies have indicated that reduced DNA repair capacity and increased DNA adduct levels are associated with increased risk of lung cancer. Nucleotide excision repair (NER) is the major pathway in humans for repairing DNA adducts induced by smoking-related carcinogens, such as benzo[a]pyrene diol epoxide. We hypothesized that genetically determined baseline expression level of genes involved in NER is associated with risk of lung cancer. In a pilot case-control study, we measured the relative expression levels of five NER genes [ERCC1, XPB/ERCC3, XPG/ERCC5, CSB/ERCC6 and XPC (ERCC, excision repair cross-complementing; CSB, Cockayne's syndrome complementary group B)] in phytohemagglutinin-stimulated peripheral lymphocytes obtained from 75 lung cancer patients and 95 controls using a newly developed multiplex RT–PCR assay. Cases and controls were matched on age, sex, ethnicity and tobacco use. The expression level of the ß-actin gene was used as an internal control for the relative quantitation. We observed a 12.2 and 12.5% decrease in the baseline expression levels of XPG/ERCC5 and CSB/ERCC6, respectively, in cases compared with controls. These differences were statistically significant (P < 0.01) when the median expression level in the controls was used as the cut-off point, the lung cancer patients were significantly more likely than the controls to have reduced expression levels of XPG/ERCC5 [odds ratio (OR), 2.32; 95% confidence interval (CI), 1.22–4.43] and CSB/ERCC6 (OR, 2.49; 95% CI, 1.28–4.84). There was also a dose–response relationship between reduced expression levels and increased lung cancer risk (trend test: P < 0.01). Our results suggest that individuals whose expression levels of XPG/ERCC5 and CSB/ERCC6 are reduced may be at higher risk of lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Woelfelschneider, O. Popanda, C. Lilla, J. Linseisen, C. Mayer, O. Celebi, J. Debus, H. Bartsch, J. Chang-Claude, and P. Schmezer A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients Carcinogenesis, September 1, 2008; 29(9): 1758 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. P. Gorlov, P. Meyer, T. Liloglou, J. Myles, M. B. Boettger, A. Cassidy, L. Girard, J. D. Minna, R. Fischer, S. Duffy, et al. Seizure 6-Like (SEZ6L) Gene and Risk for Lung Cancer Cancer Res., September 1, 2007; 67(17): 8406 - 8411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Monzo, S. Brunet, A. Urbano-Ispizua, A. Navarro, G. Perea, J. Esteve, R. Artells, M. Granell, J. Berlanga, J. M. Ribera, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia Blood, June 15, 2006; 107(12): 4871 - 4879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Mankame, R Hokanson, R Fudge, R Chowdhary, and D Busbee Altered gene expression in human cells treated with the insecticide diazinon: correlation with decreased DNA excision repair capacity Human and Experimental Toxicology, February 1, 2006; 25(2): 57 - 65. [Abstract] [PDF]
|
|
|
|
 |
|
 K.-M. Lee, J.-Y. Choi, C. Kang, C. P. Kang, S. K. Park, H. Cho, D.-Y. Cho, K.-Y. Yoo, D.-Y. Noh, S.-H. Ahn, et al. Genetic Polymorphisms of Selected DNA Repair Genes, Estrogen and Progesterone Receptor Status, and Breast Cancer Risk Clin. Cancer Res., June 15, 2005; 11(12): 4620 - 4626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenburg, I. R. Konig, R. Moessner, P. Laspe, K.-M. Thoms, U. Krueger, S. G. Khan, G. Westphal, C. Berking, M. Volkenandt, et al. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study Carcinogenesis, June 1, 2005; 26(6): 1085 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer Chest, March 1, 2005; 127(3): 978 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Suk, S. Gurubhagavatula, S. Park, W. Zhou, L. Su, T. J. Lynch, J. C. Wain, D. Neuberg, G. Liu, and D. C. Christiani Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., February 15, 2005; 11(4): 1534 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhou, G. Liu, S. Park, Z. Wang, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 491 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Koeppel, V. Poindessous, V. Lazar, E. Raymond, A. Sarasin, and A. K. Larsen Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells Clin. Cancer Res., August 15, 2004; 10(16): 5604 - 5613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann. Onc., August 1, 2004; 15(8): 1194 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gurubhagavatula, G. Liu, S. Park, W. Zhou, L. Su, J. C. Wain, T. J. Lynch, D. S. Neuberg, and D. C. Christiani XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy J. Clin. Oncol., July 1, 2004; 22(13): 2594 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. COOKE, M. D. EVANS, M. DIZDAROGLU, and J. LUNEC Oxidative DNA damage: mechanisms, mutation, and disease FASEB J, July 1, 2003; 17(10): 1195 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shen, L. Wang, M. R. Spitz, W. K. Hong, L. Mao, and Q. Wei A Novel Polymorphism in Human Cytosine DNA-Methyltransferase-3B Promoter Is Associated with an Increased Risk of Lung Cancer Cancer Res., September 1, 2002; 62(17): 4992 - 4995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shirota, J. Stoehlmacher, J. Brabender, Y.-P. Xiong, H. Uetake, K. D. Danenberg, S. Groshen, D. D. Tsao-Wei, P. V. Danenberg, and H.-J. Lenz ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy J. Clin. Oncol., December 1, 2001; 19(23): 4298 - 4304. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Emmert, T. D. Schneider, S. G. Khan, and K. H. Kraemer The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms Nucleic Acids Res., April 1, 2001; 29(7): 1443 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shen, E. M. Sturgis, S. G. Khan, Y. Qiao, T. Shahlavi, S. A. Eicher, Y. Xu, X. Wang, S. S. Strom, M. R. Spitz, et al. An Intronic Poly (AT) Polymorphism of the DNA Repair Gene XPC and Risk of Squamous Cell Carcinoma of the Head and Neck: A Case-Control Study Cancer Res., April 1, 2001; 61(8): 3321 - 3325. [Abstract] [Full Text]
|
|